, Volume 47, Issue 3, pp 536–566 | Cite as

Hyaluronic Acid

A Review of its Pharmacology and Use as a Surgical Aid in Ophthalmology, and its Therapeutic Potential in Joint Disease and Wound Healing
  • Karen L. Goa
  • Paul Benfield
Drug Evaluation



Hyaluronic acid is a naturally occurring Polysaccharide with distinct physicochemical properties which underlie its application as a viscoelastic tool in ophthalmological surgery. In cataract surgery the role of hyaluronic acid in facilitating procedures and protecting the corneal endothe-lium is well established. Some benefit has also been gained with the use of hyaluronic acid in penetrating keratoplasty, trabeculectomy, retinal reattachment and trauma surgery, although its efficacy in these indications is less well-defined in the published literature.

In addition to its lubricating and cushioning properties, demonstration of some in vitro anti-inflammatory activity and a possible disease-modifying effect for hyaluronic acid in animals has prompted its investigation as a treatment in Osteoarthritis and, to a much lesser extent, in rheumatoid arthritis. Hyaluronic acid 20mg, as weekly intra-articular injections for 3 to 7 weeks, improved knee pain and joint motion in patients with Osteoarthritis. Although this occurred to a greater degree than with placebo in most comparisons, the effects of hyaluronic acid was similar to those of placebo in the largest trial. In the few available comparisons with other agents, hyaluronic acid appeared equivalent to methylprednisolone 40mg (for 3 weeks) and to a single injection of triamcinolone 40mg. Hyaluronic acid was distinguished from other therapies by providing a sustained effect after treatment discontinuation. Together with its very good tolerability profile, these properties justify further study of hyaluronic acid in patients with Osteoarthritis.

Some limited evidence of improvement in patients with rheumatoid arthritis, and a possible healing effect of hyaluronic acid on tympanic membrane perforations, represent additional areas of interest for future investigation.

In summary, hyaluronic acid is a well-established adjunct to cataract surgery and may prove to be a promising option in the treatment of patients with Osteoarthritis. Its very good tolerability provides further impetus for examination of its potential role in an extended scope of arthritic and ophthalmological indications, and in wound healing.

Physical and Pharmacodynamic Properties, and Rationale for Clinical Use

Hyaluronic acid is a naturally occurring glycosaminoglycan which, by virtue of its viscosity, elasticity and other rheological properties, acts as a lubricating and shock absorbing fluid in joints and as an ocular lubricant. The compound also exerts some mediatory effects on cellular activity (see below). Hyaluronic acid is available in formulations of various molecular weight and concentration.

The physicochemical properties of high molecular weight hyaluronic acid provide the rationale for its use as an adjunct in ophthalmic surgery, in preventing collapse of the anterior chamber and facilitating manipulation of ocular tissues. Additionally, in animal models of cataract surgery in vitro and in vivo, hyaluronic acid 1 to 3% protected corneal endothelium from cell damage caused by synthetic lenses. Although in animal studies hyaluronic acid was both more and less effective than hydroxypropylmethylcellulose 2%, and tended to be less effective than the combination product hyaluronic acid 3%/chondroitin sulphate 4%, in clinical trials hyaluronic acid showed a protective effect at least comparable to these agents. Exogenous hyaluronic acid binds to specific sites on corneal endothelium and inhibits free radical formation after surgical damage, suggesting several mechanisms are responsible for its protective effect on the cornea.

Inflammatory reactions and increases in intraocular pressure following instillation of hyaluronic acid in animals have also occurred in humans undergoing ophthalmological surgery (see Clinical Use and Tolerability).

The rationale for investigating hyaluronic acid as a therapy in patients with rheumatoid or Osteoarthritis rests partly on the premise that supplementation of synovial fluid with exogenous product (viscosupplementation) augments the diminished lubricating and cushioning properties of endogenous substance seen in these diseases. This is supported by significant increases in synovial fluid viscosity and hyaluronic acid concentration or molecular weight seen in some arthritic patients injected with intra-articular hyaluronic acid 1%. Importantly, some anti-inflammatory activity is also apparent for high molecular weight hyaluronic acid (< 5 x 105D), as demonstrated by its inhibitory effects on cellular mediators of inflammation in vitro, and by preliminary evidence of reduced synovial membrane inflammation in a few patients with Osteoarthritis after intra-articular hyaluronic acid 20mg for 5 weeks. Modification of cellular migration by hyaluronic acid may also contribute to its apparent beneficial effects on wound healing and tympanic membrane perforation in animals and humans.

Of great interest is the finding that high molecular weight hyaluronic acid (7.5 to 20 x 105D) appears to have some ability to repair or protect cartilage from the pathophysiological processes of arthritis in animal models, and there is limited evidence suggesting such an effect in small numbers of patients with Osteoarthritis. Whether hyaluronic acid exerts a true disease-modifying effect in humans and animals is controversial and awaits confirmation.

Pharmacokinetic Properties

The pharmacokinetics of exogenously administered hyaluronic acid are poorly characterised in humans. Normal circulating serum hyaluronic acid levels are in the range 10 to 100 μg/L. Values are increased several-fold in patients with rheumatoid or Osteoarthritis in whom they correlate with clinical inflammatory signs. Hyaluronic acid is rapidly cleared from the systemic circulation, primarily through uptake by receptors on liver endothelium, and degraded to monosaccharides and their oxidation products. It is not catabolised in the eye to any significant extent, but is biotransformed by the liver after diffusion from the eye into plasma.

The elimination half-life (t1/2β) of hyaluronic acid has been calculated as 2.5 to 5.5 minutes in human plasma. As demonstrated in rabbits, the t1/2β in the eye is correlated with the volume of the formulation, but its relationship to molecular weight is equivocal. The contribution of urinary excretion to the elimination of hyaluronic acid in humans is low (μ1% of total clearance).

Clinical Use

Application of hyaluronic acid 1% as a viscoelastic adjunct in cataract surgery is of proven value. Hyaluronic acid 1% permits manipulation of ocular tissues, maintains the anterior chamber and protects corneal endothelium from damage. In the published literature, comparisons of hyaluronic acid formulations have not identified clear differences between products for effects on intraocular pressure or endothelial cell loss, and similar results for these parameters were found for hyaluronic acid 1% when compared with hydroxypropylmethylcellulose 2%. All viscoelastic substances produce transient elevations in intraocular pressure peaking within 6 to 12 hours of injection and tending to normalise within 24 hours. It is generally agreed that these elevations are lessened by postoperative aspiration of the product.

Hyaluronic acid has been of some benefit in facilitating corneal transplantation, and in limited investigations was superior to balanced saline solution. When used as internal tamponade during retinal reattachment, particularly in patients without proliferative retinopathy, hyaluronic acid has yielded a success rate of about 50%; however, this decreases over time. Based on available studies, efficacy of hyaluronic acid is equivocal in preventing collapse of the anterior chamber or choroidal detachment in patients with glaucoma undergoing trabeculectomy. The only prospective trial in such patients demonstrated that hyaluronic acid 1% significantly increased bleb formation and decreased the need for timolol eye drops, compared with no treatment. In trauma surgery, use of hyaluronic acid 1% has improved outcome and facilitated removal of traumatic hyphaema. Additionally, hyaluronic acid has shown some promise in other ophthalmological indications such as dry eye and as a drug delivery vehicle.

In patients with Osteoarthritis, knee pain and joint motion were improved with hyaluronic acid 20mg injected intra-articularly weekly for up to 7 weeks. Benefits were generally greater than with placebo; however, 1 large trial reported as an abstract showed no differences between hyaluronic acid 20mg and placebo. In limited comparisons, efficacy of hyaluronic acid 20mg was similar to that of intra-articular methylprednisolone 40mg weekly for 3 weeks and triamcinolone 40mg as a single dose.

The interesting and consistent finding that improvements seen with hyaluronic acid persisted throughout follow-up periods of 2 months to 1 year after discontinuation of treatment, is potentially advantageous and merits further investigation. Other aspects of the clinical profile of hyaluronic acid worthy of pursuit are the possible additive effects of hyaluronic acid with corti-costeroids in patients with Osteoarthritis, and preliminary evidence of efficacy in a few patients with rheumatoid arthritis. Healing rates of about 50% in patients with tympanic membrane perforations treated with hyaluronic acid otically also require confirmation.


The tolerability of hyaluronic acid 1 % as a viscoelastic tool in ophthalmological surgery is very good. Hyaluronic acid is nonimmunogenic; a mild or moderate inflammatory response occurring in virtually all patients after intraocular injection is likely provoked to some extent by the surgical procedure rather than being solely attributable to the product. Transient elevations in intraocular pressure remain within clinically acceptable levels in the majority of patients. Tolerability profiles appear similar for various formulations of hyaluronic acid and in comparison with hydroxypropylmethylcellulose.

Although less experience has been gained with hyaluronic acid in patients with Osteoarthritis, present evidence indicates the agent is also well tolerated in this population. Pain and/or swelling after intra-articular injection have occurred in up to 37% of patients in clinical trials, but resolved spontaneously. In one well-designed trial the incidence of such local reactions was similar for hyaluronic acid 20mg (37% of patients) and placebo (39%). Long term investigations of up to 1 year have shown no unwanted systemic effects or alterations in standard laboratory tests. Local inflammatory reactions have been observed in about 15 to 20% of patients with ruptured tympanic membranes receiving otic hyaluronic acid formulations.

Dosage and Administration

Hyaluronic acid is administered as an ocular injection in concentrations of 1% or greater. Total volume used is less than 1ml during cataract and other anterior segment surgery, and 2 to 4ml during posterior segment procedures. To minimise risk of postoperative elevated intraocular pressure, aspiration of the product is recommended following the procedure. Patients with rheumatoid or Osteoarthritis have received intra-articular hyaluronic acid 20mg weekly for up to 7 weeks in clinical trials. For healing of tympanic membrane perforations, hyaluronic acid 1% (0.1 to 0.3ml) has been instilled daily for an average of 10 days.


Hyaluronic Acid Intraocular Pressure Cataract Surgery Sodium Hyaluronate Corneal Endothelium 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Abatangelo G, Botti P, Del Bue M, Gei G, Samson JC, et al. Intraarticular sodium hyaluronate injections in the Pond-Nuki experimental model of Osteoarthritis in dogs. Clinical Orthopedics and Related Research 241: 278–285, 1989Google Scholar
  2. Abatangelo G, Brun P, Cortivo R. The experimental pharmacology of hyaluronic acid (hyaluronan). European Journal of Rheumatology and Inflammation, 1993, in pressGoogle Scholar
  3. Abatangelo G, Martelli M, Vecchia P. Healing of hyaluronic acid-enriched wounds: histological observations. Journal of Surgical Research 35: 410–416, 1983PubMedCrossRefGoogle Scholar
  4. Adams ME. An analysis of clinical studies of the use of crosslinked hyaluronan, hyalan, in the treatment of Osteoarthritis. Journal of Rheumatology 20 (Suppl. 39): 16–18, 1993Google Scholar
  5. Adzick NS, Longaker MT. Scarless wound healing in the fetus: the role of the extracellular matrix. Progress in Clinical Biological Research 365: 177–192, 1991Google Scholar
  6. Akatsuka M, Yamamoto Y, Tobetto K, Yasui T, Ando T. In vitro effects of hyaluronan on Prostaglandin E2 induction by interleukin1 in rabbit articular chondrocytes. Agents and Actions 38: 122–125, 1993PubMedCrossRefGoogle Scholar
  7. Alpar JJ. Comparison of Healon and Amvisc. Annals of Ophthalmology 17: 647–651, 1985PubMedGoogle Scholar
  8. Alpar JJ. Endothelium protection using Healon®, serum or air in cataract extraction and intraocular lens implantation. Journal of Ocular Therapy and Surgery 3: 229–233, 1984Google Scholar
  9. Alpar JJ. Sodium hyaluronate (Healon®) in glaucoma filtering procedures. Ophthalmic Surgery 17: 724–730, 1986PubMedGoogle Scholar
  10. Alpar JJ, Alpar AJ, Baca J, Chapman D. Comparison of Healon and Viscoat in cataract extraction and intraocular lens implantation. Ophthalmic Surgery 19: 636–642, 1988PubMedGoogle Scholar
  11. Altman R, Asch E, Bloch D, Bole G, Borenstein D, et al. Development of criteria for the classification and reporting of Osteoarthritis. Arthritis and Rheumatism 29: 1039–1049, 1986PubMedCrossRefGoogle Scholar
  12. Anmarkrud N, Bergaust B, Bulle T. The effect of Healon and timolol on early postoperative intraocular pressure after extracapsular cataract extraction with implantation of a posterior chamber lens. Acta Ophthalmologica 70: 96–100, 1992PubMedCrossRefGoogle Scholar
  13. Arshinoff S. The physical properties of ophthalmic viscoelastics in cataract surgery. Proceedings of the National Ophthalmic Speakers Program (NOSP), pp. 7–12, Montreal, Medicopea International Inc., 1992Google Scholar
  14. Assia El, Apple DJ, Lim ES, Morgan RC, Tsai JC. Removal of viscoelastic materials after experimental cataract surgery in vitro. Journal of Cataract and Refractory Surgery 18: 3–6, 1992Google Scholar
  15. Bagger-Sjöbäck D. Sodium hyaluronate application to the open inner ear: an ultrastructural investigation. American Journal of Otology 12: 35–39, 1991PubMedGoogle Scholar
  16. Bagger-Sjöbäck D, Holmquist J, Mendel L, Mercke U. Hyaluronic acid in middle ear surgery. American Journal of Otology 14: 501–506, 1993PubMedGoogle Scholar
  17. Balazs EA, Denlinger JL. Viscosupplementation: a new concept in the treatment of Osteoarthritis. Journal of Rheumatology 20 (Suppl. 39): 3–9, 1993Google Scholar
  18. Balazs EA, Freeman MI, Klöti R, Meyer-Schwickerath G, Regnault F, et al. Hyaluronic acid and replacement of vitreous and aqueous humor. Modern Problems in Ophthalmology 10: 3–21, 1972PubMedGoogle Scholar
  19. Balazs EA, Miller D, Stegmann R. Viscosurgery and the use of Na-hyaluronate in intraocular lens implantation. Presented at the International Congress and First Film Festival in Intraocular Implantation, Cannes, May 1979Google Scholar
  20. Balazs EA, Watson D, Duff IF, Roseman S. Hyaluronic acid in synovial fluid. I. Molecular parameters of hyaluronic acid in normal and arthritic human fluids. Arthritis and Rheumatism 10: 357–376, 1967Google Scholar
  21. Baldwin B, Smith TJ, Hollins JL, Pearson PA. The use of viscoelastic substances in the drainage of postoperative suprachoroidal hemorrhage. Ophthalmic Surgery 20: 504–507, 1989PubMedGoogle Scholar
  22. Bartholomew RS. Viscoelastic evacuation of traumatic hyphaema. British Journal of Ophthalmology 71: 27–29, 1987PubMedCrossRefGoogle Scholar
  23. Bernatchez SF, Camber O, Tabatabay C, Gurny R. Use of hyaluronic acid in ocular therapy. In Edman P (Ed) Biopharmaceutics of ocular drug delivery. CRC Press, Boca Raton, pp. 106–120, 1993aGoogle Scholar
  24. Bernatchez SF, Tabatabay C, Gurny R. Sodium hyaluronate 0.25% used as a vehicle increases the bioavailability of topically administered gentamicin. Graefe’s Archive for Clinical and Experimental Ophthalmology 231: 157–171, 1993bPubMedCrossRefGoogle Scholar
  25. Bertolami CN, Gay T, Clark GT, Rendell J, Shetty V, et al. Use of sodium hyaluronate in treating temporomandibular joint disorders. Journal of Oral and Maxillofacial Surgery 51: 232–242, 1993PubMedCrossRefGoogle Scholar
  26. Blondeau P. Sodium hyaluronate in trabeculectomy: a retrospective study. Canadian Journal of Ophthalmology 19: 306–309, 1984PubMedGoogle Scholar
  27. Bohnke M, Draeger J, Schneider M. Effects of Healon® and methylcellulose in protecting the cornea from mechanical trauma during surgery. Implant 4: 2–7, 1986Google Scholar
  28. Bothner H, Wik O. Rheology of intraocular solutions. In Rosen ES (Ed.) Viscoelastic materials: basic science and clinical applications. Vision and visual health care, Vol. 2, pp. 53–70, Pergamon Press, 1986Google Scholar
  29. Bourne WM, Liesegang TJ, Waller RR, Ilstrup DM. The effect of sodium hyaluronate on endothelial cell damage during extracapsular cataract extraction and posterior chamber lens implantation. American Journal of Ophthalmology 98: 759–762, 1984PubMedGoogle Scholar
  30. Bragantini A, Cassini M, De Bastiani G, Perbellini A. Controlled single-blind trial of intra-articularly injected hyaluronic acid (Hyalgan®) in Osteoarthritis of the knee. Clinical Trials Journal 24: 333–340, 1987Google Scholar
  31. Brown GC, Benson WE. Use of sodium hyaluronate for the repair of giant retinal tears. Archives of Ophthalmology 107: 1246–1249, 1989PubMedCrossRefGoogle Scholar
  32. Brown T, Laurent UBG, Fraser JRE. Turnover of hyaluronan in synovial joints: elimination of labelled hyaluronan from the knee joint of the rabbit. Experimental Physiololgy 76: 125–143, 1991Google Scholar
  33. Burd DAR, Greco RM, Regauer S, Longaker MT, Siebert JW, et al. Hyaluronan and wound healing: a new perspective. British Journal of Plastic Surgery 44: 579–584, 1991PubMedCrossRefGoogle Scholar
  34. Burke S, Sugar J, Farber MD. Comparison of the effects of two viscoelastic agents, Healon and Viscoat, on postoperative intraocular pressure after penetrating keratoplasty. Ophthalmic Surgery 21: 821–826, 1990PubMedGoogle Scholar
  35. Camarda V, Cervellini M, Pedace G, Pace M. Sodium hyaluronate in the repair of perforations of the tympanic membrane. Clinical Therapeutics 11: 744–754, 1989PubMedGoogle Scholar
  36. Carney SL, Billingham MEJ, Muir H, Sandy JD. Structure of newly synthesised (35S)-proteoglycans and (35S)-proteoglycan turnover products of cartilage expiant cultures from dogs with experimental Osteoarthritis. Journal of Orthopedic Research 3: 140–147, 1985CrossRefGoogle Scholar
  37. Carrabba M, Paresce E, Angelini M. The safety and efficacy of different dose schedules of hyaluronic acid in the treatment of painful Osteoarthritis of the knee with joint effusion. European Journal of Rheumatology and Inflammation, in press, 1993Google Scholar
  38. Carrabba M, Paresce E, Angelini M, Zamboni AM, Bragantini A, et al. The intra-articular treatment of Osteoarthritis of the knee. A comparative study between hyaluronic acid (Hyalgan®) and orgotein. European Journal of Rheumatology and Inflammation 12: 47–57, 1992Google Scholar
  39. Cavaliere S, Spampinato D, Caruso P, Dal Bello A, Reibaldi A, et al. Effects of hyaluronic acid fractions in the rabbit eye. Annals of Ophthalmology 22: 429–431, 1990PubMedGoogle Scholar
  40. Celleno L, Piperno S, Bracaglia R. Esperienze clinico-sperimentali suH’uso dell’acido ialuronico nei processi riparativi cutanei. Giornale Italiano di Dermatologia e Venereologia 120: 47–56, 1985Google Scholar
  41. Charteris DG, McConnell JMS, Adams AD. Effect of sodium hyaluronate on trabeculectomy filtration blebs. Journal of the College of Surgery in Edinburgh 36: 107–108, 1991Google Scholar
  42. Cherfan GM, Rich WJ, Wright G. Raised intraocular pressure and other problems with sodium hyaluronate and cataract surgery. Transactions of the Ophthalmological Society (UK) 103: 277–279, 1983Google Scholar
  43. Chung J-H, Fagerholm P, Lindström B. Hyaluronate in healing of corneal alkali wound in the rabbit. Experimental Eye Research 48: 569–576, 1989PubMedCrossRefGoogle Scholar
  44. Clark RAF. Cutaneous tissue repair: basic biologic considerations. Journal of the American Academy of Dermatology 13: 701–725, 1985PubMedCrossRefGoogle Scholar
  45. Clorfeine GS, Parker WT. Use of Healon in eye muscle surgery with adjustable sutures. Annals of Ophthalmology 19: 215–217, 1987PubMedGoogle Scholar
  46. Cobo M, Beaty N. VitraxTM (sodium hyaluronate) in anterior segment surgery: a review and clinical study summary. Advances in Therapy 7: 51–60, 1990PubMedGoogle Scholar
  47. Constable IJ, Swann DS. Biological vitreous substitutes. Archives of Ophthalomology 88: 544–548, 1972CrossRefGoogle Scholar
  48. Cooper EH, Rathbone BJ. Clinical significance of the immunometric measurements of hyaluronic acid. Annals of Clinical Biochemistry 27: 444–451, 1990PubMedGoogle Scholar
  49. Cortivo R, De Galateo A, Castellani I, Brun P, Giro MG, et al. Hyaluronic acid promotes chick embryo fibroblast and chondroblast expression. Cell Biology International Reports 14: 111–122, 1990PubMedCrossRefGoogle Scholar
  50. Cortivo R, Govoni E, De Galateo A, Brun P, Abatangelo G. Hyaluronate reverses inhibition of proteoglycan synthesis by oxygen free-radicals in cultured embryonic cartilage. Abstract no. 46. European Journal of Cell Biology 49 (Suppl. 28): 18, 1989Google Scholar
  51. Creamer P, Sharif M, George E, Cushnaghan J, Dieppe P. Intra-articular hyaluronate reduces keratan sulphate levels in osteoarthritic (OA) synovial fluid. Abstract no. B93. Presented at the 56th Annual Scientific Meeting of the American College of Rheumatology, October 11–15, Atlanta, 1992Google Scholar
  52. Dahl LB, Dahl IMS, Engström-Laurent A, Granath K. Concentration and molecular weight of sodium hyaluronate in synovial fluid from patients with rheumatoid arthritis and other arthropathies. Annals of the Rheumatic Diseases 44: 817–822, 1985PubMedCrossRefGoogle Scholar
  53. DeLuise VP, Peterson WS. The use of topical Healon® in the management of refractory dry-eye syndrome. Annals of Ophthalmology 16: 823–824, 1984PubMedGoogle Scholar
  54. Denlinger JL, El-Mofty AA, Balazs EA. Replacement of the liquid vitreous with sodium hyaluronate in monkeys. Experimental Eye Research 30: 101–117, 1980CrossRefGoogle Scholar
  55. Dixon A St.J, Jacoby RK, Barry H, Hamilton EBD. Clinical trial of intra-articular injection of sodium hyaluronate in patients with Osteoarthritis of the knee. Current Medical Research and Opinion 11: 205–213, 1988CrossRefGoogle Scholar
  56. Dougados M, Nguyen M, Listrat V, Amor B. High molecular weight sodium hyaluronate (hylectin) in Osteoarthritis of the knee: a 1 year placebo-controlled trial. Osteoarthritis and Cartilage 1: 97–103, 1993PubMedCrossRefGoogle Scholar
  57. Eisner G. Use of viscoelastic tools in ophthalmic surgery. In Eisner G (Ed.) Ophthalmic Viscosurgery, pp. 21–37, Medicopea International Inc., 1986Google Scholar
  58. Embriano PJ. Postoperative presssures after phacoemulsificaton: sodium hyaluronate vs. sodium chondroitin sulfate-sodium hyaluronate. Annals of Ophthalmology 21: 85–90, 1989Google Scholar
  59. Engström-Laurent A, Hällgren R. Circulating hyaluronic acid levels vary with physical activity in healthy subjects and in rheumatoid arthritis patients. Arthritis and Rheumatism 30: 1333–1338, 1987PubMedCrossRefGoogle Scholar
  60. Engström-Laurent A, Hällgren R. Circulating hyaluronate in rheumatoid arthritis: relationship to inflammatory activity and the effect of corticosteroid therapy. Annals of the Rheumatic Diseases 44: 83–88, 1985PubMedCrossRefGoogle Scholar
  61. Engström-Laurent A, Laurent UBG, Lilja K, Laurent TC. Concentration of sodium hyaluronate in serum. Scandinavian Journal of Clinical Laboratory Investigation 45: 497–504, 1985CrossRefGoogle Scholar
  62. Fagerholm P, Koul S, Trocmé S. Corneal endothelial protection by heparin and sodium hyaluronate surface coating of PMMA intraocular lenses. Acta Ophthalmologica 65 (Suppl. 182): 110–114, 1987CrossRefGoogle Scholar
  63. Ferretti RG, Martini A, Morra B, Marchiori C, Tombolini A, et al. Hyaluronic acid in tympanic membrane perforation repair. Results of two multicenter, controlled clincal trials. Abstract. Presented at the 2nd European Congress of Oto-Rhino-Laryngology and Cervico Facial Surgery, Sorrento, Jun 6–10, 1992Google Scholar
  64. Folk JC, Packer AJ, Weingeist TA, Howcroft MJ. Sodium hyaluronate (Healon®) in closed vitrectomy. Ophthalmic Surgery 17: 299–306, 1986PubMedGoogle Scholar
  65. Forrester JV, Balazs EA. Inhibition of phagocytosis by high molecular weight hyaluronate. Immunology 40: 435–446, 1980PubMedGoogle Scholar
  66. Foschi D, Castoldi L, Radaelli E, Abelli P, Calderini G, et al. Hyaluronic acid prevents oxygen free-radical damage to granulation tissue: a study in rats. International Journal of Tissue Reactions 12: 333–339, 1990PubMedGoogle Scholar
  67. Fraser JRE, Engström-Laurent A, Nyberg A, Laurent TC. Removal of hyaluronic acid from the circulation in rheumatoid disease and primary biliary cirrhosis. Journal of Laboratory and Clinical Medicine 107: 79–85, 1986PubMedGoogle Scholar
  68. Fraser JRE, Kimpton WG, Laurent TC, Cahill RNP, Vakakis N. Uptake and degradation of hyaluronan in lymphatic tissue. Biochemical Journal 256: 153–158, 1988PubMedGoogle Scholar
  69. Fraser JRE, Kimpton WG, Pierscionek BK, Cahill RNP. The kinetics of hyaluronan in normal and acutely inflamed synovial joints: observations with experimental arthritis in sheep. Seminars in Arthritis and Rheumatism 22 (Suppl. 1): 9–17, 1993PubMedCrossRefGoogle Scholar
  70. Fraser JRE, Laurent TC, Engström-Laurent A, Laurent UGB. Elimination of hyaluronic acid from the blood stream in the human. Clinical and Experimental Pharmacology & Physiology 11: 17–25, 1984CrossRefGoogle Scholar
  71. Frizziero L, Focherini MC, Govoni E. Hyaluronic acid versus methylprednisolone intra-articular treatment in knee Osteoarthritis: a comparative, integrated in vivo and ex vivo morphological assessment by arthroscopy and histopathology. Abstract. Revista Espanola de Reumatologia 20 (Suppl.1): 575, 1993Google Scholar
  72. Frizziero L, Zizzi F, Govoni E, Perbellini A. Destructive inflammatory Osteoarthritis of the knee joint. Microarthroscopic and ultra-structural study of the articular environment. Abstract. Revue du Rhumatisme 55: 830, 1988Google Scholar
  73. Fry LL. Postoperative intraocular pressure rises: a comparison of Healon, Amvisc and Viscoat. Journal of Cataract and Refractory Surgery 15: 415–420, 1989Google Scholar
  74. Gandolfi SA, Massari A, Orsoni JG. Low-molecular-weight sodium hyaluronate in the treatment of bacterial corneal ulcers. Graefe’.s Archive for Clinical and Experimental Ophthalmology 230: 20–23, 1992PubMedCrossRefGoogle Scholar
  75. Gerber SL, Cantor LB. Slit lamp reformation of the anterior chamber following trabeculectomy. Ophthalmic Surgery 21: 404–406, 1990PubMedGoogle Scholar
  76. Gerke E, Meyer-Schwickerath G, Wessing A. Healon in retinal detachment with proliferative vitreoretinopathy. Graefe’s Archive for Clinical and Experimental Ophthalmology 221: 241–243, 1984PubMedCrossRefGoogle Scholar
  77. Ghosh P. The role of hyaluronic acid (hyaluronan) in health and disease — interactions with cartilage components and cells. European Journal of Rheumatology and Inflammaton, 1993, in pressGoogle Scholar
  78. Ghosh P, Brooks P. Chondroprotection — exploring the concept. Journal of Rheumatology 18: 161–165, 1991PubMedGoogle Scholar
  79. Ghosh PK, Read R, Armstrong S, Wilson D, Marshall R, et al. The effects of intraarticular administration of hyaluronan in a model of early Osteoarthritis in sheep. I. Gait analysis and radiological and morphological studies. Seminars in Arthritis and Rheumatism 22 (Suppl. 1): 18–30, 1993PubMedCrossRefGoogle Scholar
  80. Glasser DB, Katz HR, Boyd JE, Langdon JD, Shobe SL, et al. Protective effects of viscous solutions in phacoemulsification and traumatic lens implantation. Archives of Ophthalmology 107: 1047–1051, 1989PubMedCrossRefGoogle Scholar
  81. Glasser DB, Matsuda M, Edelhauser HE A comparison of the efficacy and toxicity of and intraocular pressure response to viscous solutions in the anterior chamber. Archives of Ophthalmology 104: 1819–1824, 1986PubMedCrossRefGoogle Scholar
  82. Glasser DB, Osborn DC, Nordeen JF, Min Y-I. Endothelial protection and viscoelastic retention during phacoemulsification and intraocular lens implantation. Archives of Ophthalmology 109: 1438–1440, 1991PubMedCrossRefGoogle Scholar
  83. Gnad H, Kiemen UM, Radda TM. Healon also innere Tamponade in der Netzhautchirurgie. Klinische Monatsblatter fuer AugenheilKunde 183: 184–186, 1983CrossRefGoogle Scholar
  84. Goldberg RL, Huff JP, Lenz ME, Glickman P, Katz R, et al. Elevated plasma levels of hyaluronate in patients with Osteoarthritis and rheumatoid arthritis. Arthritis and Rheumatism 34: 799–807, 1991PubMedCrossRefGoogle Scholar
  85. Goldberg RL, Toole BP. Hyaluronate inhibition of cell proliferation. Arthritis and Rheumatism 30: 769–778, 1987PubMedCrossRefGoogle Scholar
  86. Graue EL, Polack FM, Balazs EA. The protective effect of Nahyaluronate to corneal endothelium. Experimental Eye Research 1: 119–127, 1980CrossRefGoogle Scholar
  87. Grecomoro G, Martorana U, Di Marco C. Intra-articular treatment with sodium hyaluronate in gonarthrosis: a controlled clinical trial versus placebo. Pharmatherapeutica 5: 137–141, 1987PubMedGoogle Scholar
  88. Grecomoro G, Piccione F, Letizia G. Therapeutic synergism between hyaluronic acid and dexamethasone in the intra-articular treatment of Osteoarthritis of the knee: a preliminary open study. Current Medical Research and Opinion 13: 49–55, 1992PubMedCrossRefGoogle Scholar
  89. Hashimoto Y, et al. Multicenter clinical studies of ARTZ® (high molecular weight sodium hyaluronate) in the long term treatment of Osteoarthritis of the knee: including x-ray analysis. In Japanese. Yakuri to Chiryo 20: 347–360, 1992Google Scholar
  90. Härfstrand A, Molander N, Stenevi U, Apple D, Schenholm M, et al. Evidence of hyaluronic acid and hyaluronic acid binding sites on human corneal endothelium. Journal of Cataract and Refractory Surgery 18: 265–269, 1992Google Scholar
  91. Hazariwala K, Mortimer CB, Slomovic AR. Comparison of 2% hydroxypropylmethylcellulose and 1% sodium hyaluronate in implant surgery. Canadian Journal of Ophthalmology 23: 259–261, 1988PubMedGoogle Scholar
  92. Hellström S, Bloom GD, Berghem L, Stenfors L-E, Söderberg O. A comparison of hyaluronan and fibronectin in the healing of tympanic membrane perforations. European Archives of Otorhinolaryngology 248: 230–235, 1991PubMedCrossRefGoogle Scholar
  93. Hellström S, Laurent C. Hyaluronan and healing of tympanic membrane perforations. Acta Otolaryngologica (Stockholm) 442 (Suppl. 5): 54–61, 1987CrossRefGoogle Scholar
  94. Hollands RH, Drance SM, House PH, Schulzer M. Control of intraocular pressure after cataract extraction. Canadian Journal of Ophthalmology 25: 128–132, 1990PubMedGoogle Scholar
  95. Holmberg ÅS, Philipson BT. Sodium hyaluronate in cataract surgery. I. Report on the use of Healon® in two different types of intracapsu-lar cataract surgery. Ophthalmology 91: 45–52, 1984aPubMedGoogle Scholar
  96. Holmberg AS, Philipson BT. Sodium hyaluronate in cataract surgery. II. Report on the use of Healon®in extracapsular cataract surgery using phacoemulsification. Ophthalmology 91: 53–59, 1984bPubMedGoogle Scholar
  97. Holst A, Rolfsen W, Svensson B, Öllinger K, Lundgren B. Formation of free radicals during phacoemulsification. Current Eye Research 12: 359–365, 1993PubMedCrossRefGoogle Scholar
  98. Honma T, Maeda F, Kojima A, Ouchi F. Clinical efficacy of intraarticular injection of high molecular weight sodium hyaluronate (ARTZ®) in treatment of Osteoarthritis of the knee. In Japanese. Shinyaku to Chiryo 17: 451–466, 1989Google Scholar
  99. Hoover DL, Giangiacomo J, Benson RL. Descemet’s membrane detachment by sodium hyaluronate. Archives of Ophthalmology 103: 805–808, 1985PubMedCrossRefGoogle Scholar
  100. Hørslev-Petersen K, Bentsen KD, Engström-Laurent A, Junker P, Halberg P, et al. Serum amino terminal type III procollagen peptide and serum hyaluronan in rheumatoid arthritis: relation to clinical and serological parameters of inflammation during 8 and 24 months’ treatment with levamisole, penicillamine, or azathioprine. Annals of the Rheumatic Diseases 47: 116–126, 1988PubMedCrossRefGoogle Scholar
  101. Hultsch E. The scope of hyaluronic acid as an experimental intraocular implant. Ophthalmology 87: 706–712, 1980PubMedGoogle Scholar
  102. Hung SO. Role of sodium hyaluronate (Healonid) in triangular flap trabeculectomy. British Journal of Ophthalmology 69: 46–50, 1985PubMedCrossRefGoogle Scholar
  103. Imai Y, Odajima R, Inoue Y, Shishiba Y Effect of growth factors on hyaluronan and proteoglycan synthesis by retroocular tissue fibro-blasts of Graves’ ophthalmopathy in culture. Acta Endocrinologica 126: 541–552, 1992PubMedGoogle Scholar
  104. Insler MS. A new use for sodium hyaluronate (Healon®) in penetrating keratoplasty. Annals of Ophthalmology 17: 106–108, 1985PubMedGoogle Scholar
  105. Isdale AH, Hordon LD, Bird HA, Wright V. Intra-articular hyaluronate (Healon): a dose-ranging study in rheumatoid arthritis and Osteoarthritis. Journal of Drug Development 4: 93–99, 1991Google Scholar
  106. Iwata H. Pharmacologic and clinical aspects of intraarticular injection of hyaluronate. Clinical Orthopaedics and Related Research 289: 285–291, 1993PubMedGoogle Scholar
  107. Jones AC, Patrick M, Doherty S, Doherty M. A double-blind trial of intra-articular hyaluronic acid (HA) versus intra-articular triam-cinolone hexacetonide (TH) in knee Osteoarthritis (OA). Abstract. Arthritis and Rheumatism 35 (Suppl.): S132, 1992Google Scholar
  108. Kahaly G, Stover C, Beyer J, Otto E. In vitro synthesis of glycosaminoglycans in endocrine ophthalmopathy. Acta Endocrinologica 127: 397–402, 1992PubMedGoogle Scholar
  109. Kammann J, Dornbach G, Vollenberg C, Hille P. Kontrollirte klinische Studie zweier viskoelastischer Substanzen. Fortschritte Ophthalmologie 88: 438–441, 1991Google Scholar
  110. Kawabata M, Igarashi M, Mikami R, Ninomiya S, Oda H, et al. Clinical evaluations of SLM-10 (sodium hyaluronate injection) in patients with Osteoarthritis of the knee. Yakuri to Chiryo 21: 257–283, 1993Google Scholar
  111. Kido H, Maeyama K, Tagawa T, Tomita T, Ito A, et al. Effect of high molecular weight sodium hyaluronate (SL-1010) on experimental Osteoarthritis induced by immobilization of rabbit knee joint. In Japanese. Japanese Journal of Pharmacology and Therapeutics 21 (Suppl. 2): 115–121, 1993Google Scholar
  112. Kikuchi T, Obara T, Yamaguchi T, Shimizu N, Iidaka T, et al. Effect of sodium hyaluronate with high molecular weight (SL-1010) on the experimental knee Osteoarthritis produced by transection of anterior cruciate ligament in beagle dogs. In Japanese. Pharmacometrics 44: 547–557, 1992Google Scholar
  113. Kikuchi T, Yamaguchi T, Sakakibara Y, Itoh H, Iwata H, et al. Therapeutic effect of high molecular weight sodium hyaluronate (SL-1010) on the experimental Osteoarthritis induced by rabbit knee immobilization. In Japanese. Japanese Pharmacology and Therapeutics 21 (Suppl. 2): 123–131, 1993Google Scholar
  114. King SR, Hickerson WL, Proctor KG. Beneficial actions of exogenous hyaluronic acid on wound healing. Surgery 109: 76–84, 1991PubMedGoogle Scholar
  115. Koch DD, Liu JF, Glasser DB, Merin LM, Haft E. A comparison of corneal endothelial changes after use of Healon or Viscoat during phacoemulsification. American Journal of Ophthalmology 115: 188–201, 1993PubMedGoogle Scholar
  116. Kondo T, Chichibu K, Usuki H, Matsuura T, Shichijo S, et al. Rapid assay of hyaluronic acid in serum. In Japanese. Rinsho Byori 39: 536–540, 1991Google Scholar
  117. Konttinen YT, Saari H, Honkanen VEA, Szocsik K, Mussalo-Rauhamaa H, et al. Serum baseline hyaluronate and disease activity in rheumatoid arthritis. Clinica Chimica Acta 193: 39–48, 1990CrossRefGoogle Scholar
  118. Koster R, Stilma JS. Comparison of vitreous replacement with Healon® and with HPMC in rabbits’ eyes. Documenta Ophthalmologica 61: 247–253, 1986aPubMedCrossRefGoogle Scholar
  119. Koster R, Stilma JS. Healon® as intravitreal substitute in retinal detachment surgery in 40 patients. Documenta Ophthalmologica 64: 13–17, 1986bPubMedCrossRefGoogle Scholar
  120. Kvam C, Granese D, Flaibani A, Zanetti F, Paoletti S. Purification and characterization of hyaluronan from synovial fluid. Analytical Biochemistry 211: 44–49, 1993PubMedCrossRefGoogle Scholar
  121. Laflamme MY, Swieca R. A comparative study of two preservative-free tear substitutes in the management of severe dry eye. Canadian Journal of Ophthalmology 23: 174–176, 1988PubMedGoogle Scholar
  122. Lane SS, Naylor DW, Kullerstrand LJ, Knauth K, Lindstrom RL. Prospective comparison of the effects of Occucoat, Viscoat, and Healon on intraocular pressure and endothelial cell loss. Journal of Cataract and Refractive Surgery 17: 21–26, 1991PubMedGoogle Scholar
  123. Lang E, Mark D, Miller FA, Miller D, Wik O. Shear flow characteristics of sodium hyaluronate. Archives of Ophthalmology 102: 1079–1082, 1984PubMedCrossRefGoogle Scholar
  124. Langerman DW. Sodium hyaluronate vitrectomy. Journal of Cataract and Refractive Surgery 12: 69–72, 1986PubMedGoogle Scholar
  125. Laurent UBG. Hyaluronate in human aqueous humor. Archives of Ophthalmology 101: 129–130, 1983PubMedCrossRefGoogle Scholar
  126. Laurent UBG, Dahl LB, Lilja K. Hyaluronan injected in the anterior chamber of the eye is catabolized in the liver. Experimental Eye Research 57: 435–440, 1993PubMedCrossRefGoogle Scholar
  127. Laurent UBG, Fraser JRE. Disappearance of concentrated hyaluronan from the anterior chamber of monkey eyes. Experimental Eye Research 51: 65–69, 1990PubMedCrossRefGoogle Scholar
  128. Laurent UBG, Fraser JRE. Turnover of hyaluronate in the aqueous humor and vitreous body of the rabbit. Experimental Eye Research 36: 493–504, 1983PubMedCrossRefGoogle Scholar
  129. Laurent TC, Fraser JRE, Pertoft H, Smedsrod B. Binding of hyaluronate and chondroitin sulphate to liver endothelial cells. Biochemical Journal 234: 653–658, 1986PubMedGoogle Scholar
  130. Laurent UBG, Laurent TC. On the origin of hyaluronate in blood. Biochemistry International 2: 195–199, 1981Google Scholar
  131. Laurent TC, Lilja K, Brunnberg L, Engström-Laurent A, Laurent UBG, et al. Urinary excretion of hyaluronan in man. Scandinavian Journal of Clinical and Laboratory Investigation 47: 793–799, 1987PubMedCrossRefGoogle Scholar
  132. Leardini G, Perbellini A, Franceschini M, Mattara L. Intra-articular injections of hyaluronic acid in the treatment of painful shoulder. Clinical Therapeutics 10: 521–525, 1988PubMedGoogle Scholar
  133. Leardini G, Mattara L, Franceschini F, Perbellini A. Intra-articular treatment of knee Osteoarthritis. A comparative study between hyaluronic acid and 6-methylprednisolone acetate. Clinical and Experimental Rheumatology 9: 375–381, 1991Google Scholar
  134. Lequesne MG, Mery C, Samson M, Gerard P. Indexes of severity for Osteoarthritis of the hip and knee. Scandinavian Journal of Rheumatology (Suppl. 65): 85–89, 1987Google Scholar
  135. Levesque H, Delpech B, Le Loet X, Deshayes P. Serum hyaluronate in rheumatoid arthritis: study by affino-immunoenzymatic assay. British Journal of Rheumatology 27: 445–449, 1988PubMedCrossRefGoogle Scholar
  136. Liesegang TJ. Viscoelastic substances in ophthalmology. Survey of Ophthalmology 34: 268–293, 1990PubMedCrossRefGoogle Scholar
  137. Liesegang TJ, Bourne WM, Ilstrup D. The use of hydroxypropyl methylcellulose in extracapsular cataract extraction with intraocular lens implantation. American Journal of Ophthalmology 102: 723–726, 1986PubMedGoogle Scholar
  138. Limberg MB, McCaa C, Kissling GE, Kaufman HE. Topical application of hyaluronic acid and chondroitin sulfate in the treatment of dry eyes. American Journal of Ophthalmology 103: 194–197, 1987PubMedGoogle Scholar
  139. Lindqvist U, Chichibu K, Delpech B, Goldberg B, Knudson W, et al. Seven different assays of hyaluronan compared for clinical utility. Clinical Chemistry 38: 127–132, 1992PubMedGoogle Scholar
  140. Lindqvist U, Engström-Laurent A, Laurent U, Nyberg A, Björklund U, et al. The diurnal variation of serum hyaluronan in health and disease. Scandinavian Journal of Clinical and Laboratory Investigation 48: 765–770, 1988PubMedCrossRefGoogle Scholar
  141. Longaker MT, Harrison MR, Crombleholme TM, Langer JC, Decker M, et al. Studies in fetal wound healing: I. A factor in fetal serum that stimulates deposition of hyaluronic acid. Journal of Pediatric Surgery 24: 789–792, 1989Google Scholar
  142. Madsen K, Schenholm M, Jahnke G, Tengblad A. Hyaluronate binding to intact corneas and cultured endothelial cells. Investigative Ophthalmology & Visual Science 30: 2132–2137, 1989Google Scholar
  143. Maguen E, Nesburn A, Macy JI. Combined use of sodium hyaluronate and tissue adhesive in penetrating keratoplasty of corneal perforations. Ophthalmic Surgery 15: 55–57, 1984PubMedGoogle Scholar
  144. Martini A, Cimino A, Drusian A, Ferretti RG, Magnolfi G, et al. The use of hyaluronic acid in tympanic membrane repair. Amulticenter clinical trial vs. placebo. Abstract. Presented at the Fifth International Symposium on Recent Advances in Otitis Media. Fort Lauderdale, May 20–24, 1991Google Scholar
  145. Martini A, Rubini R, Ferretti RG, Govoni E, Schiavinato A, et al. Comparative ototoxic potential of hyaluronic acid and methylcellulose. Acta Otolaryngologica (Stockholm): 112: 278–283, 1992Google Scholar
  146. Mast BA, Flood LC, Haynes JH, Depalma RL, Cohen IK, et al. Hyaluronic acid is a major component of the matrix of fetal rabbit skin and wounds: implications for healing by regeneration. Matrix 11: 63–68, 1991PubMedCrossRefGoogle Scholar
  147. Mast BA, Haynes JH, Krummel TM, Diegelmann RF, Cohen IK. In vivo degradation of fetal wound hyaluronic acid results in increased fibroplasia, collagen deposition and neovascularization. Plastic and Reconstructive Surgery 89: 503–509, 1992PubMedCrossRefGoogle Scholar
  148. Masuda K, Sawa M, Fukado Y, Sakimoto T. Phase II clinical study of sodium hyaluronate in penetrating keratoplasty. In Japanese. Yakuri to Chiryo 19: 365–375, 1991Google Scholar
  149. McLeod D, James CR. Viscodelamination at the vitreoretinal juncture in severe diabetic eye disease. British Journal of Ophthalmology 72: 413–419, 1988PubMedCrossRefGoogle Scholar
  150. Mengher LS, Pandher KS, Bron AJ, Davey CC. Effect of sodium hyaluronate (0.1%) on break-up time (NIBUT) in patients with dry eyes. British Journal of Ophthalmology 70: 442–447, 1986PubMedCrossRefGoogle Scholar
  151. Mensitieri M, Ambrosio L, Iannace S, Perbellini A, Nicolais L. Viscoelastic evaluation of different knee Osteoarthritis therapies. In Bonfield (Ed) Journal of Material Science: Materials in Medicine, in press, 1993Google Scholar
  152. Miller D, Stegmann R. Use of sodium hyaluronate in human IOL implantation. Annals of Ophthalmology 13: 811–815, 1981PubMedGoogle Scholar
  153. Miura T, Tanba S, Yoshizawa H, Matsui N, Nagaya I. High molecular weight Na-hyaluronate intra-articular injection for patients with rheumatoid arthritis combined with Osteoarthritis of the knee joint. In Japanese. Igaku to Yakugaku 29: 1061–1071, 1993Google Scholar
  154. Miyauchi S, Iwata S. Biochemical studies on the use of sodium hyaluronate in the anterior eye segment. IV. The protective efficacy of the corneal endothelium. Current Eye Research 3: 1063–1067, 1984Google Scholar
  155. Miyauchi S, Iwata S. Evaluations on the usefulness of viscous agents in anterior segment surgery. II. Effect on intraocular pressure and clearance from the anterior chamber. Journal of Ocular Pharmacology 5: 221–232, 1989Google Scholar
  156. Molander N, Ehinger B, Rolfsen W, Härfstrand A, Stenevi U. Histochemical identification of hyaluronan in the rabbit anterior segment during the healing period after extracapsular lens extraction. Acta Ophthalmologica 71: 336–346, 1993aPubMedCrossRefGoogle Scholar
  157. Molander N, Lindquist U, Lind M-L, Stenevi U, Ehinger B. Influence of anterior segment trauma on endogenous hyaluronan in the rabbit cornea and aqueous. European Journal of Implant and Refractory Surgery 5: 121–127, 1993bGoogle Scholar
  158. Molander N, Lindquist U, Stenevi U, von Malmborg A, Ehinger B. Influence of radial keratotomy on endogenous hyaluronan in cornea and aqueous humour. Refractive and Corneal Surgery 9: 358–365, 1993cPubMedGoogle Scholar
  159. Morisawa K, Takagi K. Clinical evaluation of SLM-10 (high molecular weight sodium hyaluronate) on periarthritis of the shoulder. In Japanese. Japanese Pharmacology and Therapeutics 21 (Suppl. 2): 355–365, 1993Google Scholar
  160. Muir MGK, Sherrard ES, Andrews V, Steele AD. Air, methylcellulose, sodium hyaluronate and the corneal endothelium. Eye 1: 480–486, 1987CrossRefGoogle Scholar
  161. Musch DC, Meyer R, Sugar A, Soong HK. Endothelial rejection following penetrating keratoplasty using Healon or BSS. Cornea 9: 305–311, 1990PubMedCrossRefGoogle Scholar
  162. Næser K, Thim K, Hansen TE, Degn T, Madsen S, et al. Intraocular pressure in the first days after implantation of posterior chamber lenses with the use of sodium hyaluronate (Healon®). Acta Ophthalmologica 64: 330–337, 1986PubMedCrossRefGoogle Scholar
  163. Nakamura M, Hikida M, Nakano T. Concentration and molecular weight dependency of rabbit corneal epithelial wound healing on hyaluronan. Current Eye Research 11: 981–986, 1992PubMedCrossRefGoogle Scholar
  164. Namiki O, Toyoshima H, Morisaki N. Therapeutic effect of intra-articular injection of high molecular weight hyaluronic acid on Osteoarthritis of the knee. International Journal of Clinical Pharmacology, Therapy and Toxicology 20: 501–507, 1982Google Scholar
  165. Nelson JD, Farris RL. Sodium hyaluronate and polyvinyl alcohol artificial tear preparation. Archives of Ophthalmology 106: 484–487, 1988PubMedCrossRefGoogle Scholar
  166. Niethard FU, Graf J, Neusel E, Schneider E. Clinical efficacy of hyaluronic acid in Osteoarthritis. Abstract. Revista Espanola de Reumatologia 20 (Suppl. 1): 576, 1993Google Scholar
  167. Nishida T, Nakamura M, Mishima H, Otori T. Hyaluronan stimulates corneal epithelial migration. Experimental Eye Research 53: 753–758, 1991PubMedCrossRefGoogle Scholar
  168. Obara T, Yamaguchi T, Moriya Y, Namba K. Tissue distribution of fluoroscein-labeled sodium hyaluronate in experimentally-induced Osteoarthritis. In Japanese. Japanese Pharmacology and Therapeutics 21 (Suppl. 2): 193–200, 1993Google Scholar
  169. Ohguro N, Matsuda M, Kinoshita S. The effects of denatured sodium hyaluronate on the corneal endothelium in cats. American Journal of Ophthalmology 112: 424–430, 1991PubMedGoogle Scholar
  170. Olsen EB, Trier K, Jørgensen B, Brok K-E, Ammitzbøll T. The effect of hyaluronic acid on cartilage in the immobilized rabbit knee. Acta Orthopaedica Scandinavica 62: 323–326, 1991PubMedCrossRefGoogle Scholar
  171. Ono K, Nakahara H, Yonenobu K, Ochi T, Hongo I, et al. Study of the effect of intra-articular injection of high molecular weight sodium hyaluronate (SLM-10) on Osteoarthritis of the knee joint. In Japanese. Japanese Pharmacology and Therapeutics 21 (Suppl. 2): 333–354, 1993aGoogle Scholar
  172. Ono K, Hirasawa Y, Matsui N, Moriya H. A study of the effect of intra-articular long term injection of high molecular weight sodium hyaluronate (SLM-10) on Osteoarthritis of the knee joint. In Japanese. Japanese Pharmacology and Therapeutics 21 (Suppl. 2): 409–424, 1993bGoogle Scholar
  173. Östberg A, Törnqvist G. Management of detachment of Descemet’s membrane caused by injection of hyaluronic acid. Ophthalmic Surgery 20: 885–886, 1989PubMedGoogle Scholar
  174. Paimela L, Heiskanen A, Kurki P, Helve T, Leirsalo-Repo M. Serum hyaluronate level as a predictor of radiologic progression in early rheumatoid arthritis. Arthritis and Rheumatism 34: 815–821, 1991PubMedCrossRefGoogle Scholar
  175. Pape LG, Balazs EA. The use of sodium hyaluronate (Healon®) in human anterior segment surgery. Ophthalmology 87: 699–705, 1980PubMedGoogle Scholar
  176. Parkes HG, Grootveld MC, Henderson EB, Farrell A, Blake DR. Oxidative damage to synovial fluid from the inflamed rheumatoid joint detected by H NMR spectroscopy. Journal of Pharmaceutical & Biomédical Analysis 9: 75–82, 1991CrossRefGoogle Scholar
  177. Partsch G, Schwarzer Ch, Neumüller J, Dunky A, Petera P, et al. Modulation of the migration and Chemotaxis of PMN cells by hyaluronic acid. In German. Zeitschrift für Rheumatologie 48: 123–128, 1989Google Scholar
  178. Pasquali Ronchetti L, Frizziero L, Focherini MC, Guerra D. The synovial membrane after treatment with hyaluronic acid and 6-methylprednisolone. Abstract. Revista Espanola de Reumatologia 20 (Suppl. 1): 574, 1993Google Scholar
  179. Passarini B, Tosti A, Fanti PA, Varotti C. Effetto dell’acido ialuronico sul processo riparativo delie ulcere trofiche. Giornale Italiano di Dermatologia e Venereologia 117: 27–30, 1982Google Scholar
  180. Passo MS, Ernest JT, Goldstick TK. Hyaluronate increases intraocular pressure when used in cataract extraction. British Journal of Ophthalmology 69: 572–575, 1985PubMedCrossRefGoogle Scholar
  181. Pedersen Oø. Comparison of the protective effects of methylcellulose and sodium hyaluronate on corneal swelling following phacoemulsification of senile cataracts. Journal of Cataract and Refractive Surgery 16: 594–596, 1990PubMedGoogle Scholar
  182. Pelletier J-P, Martel-Pelletier J. The pathophysiology of Osteoarthritis and the implication of the use of hyaluronan and hylan as therapeutic agents in viscosupplementation. Journal of Rheumatology 20 (Suppl. 39): 19–24, 1993Google Scholar
  183. Peluso GF, Perbellini A, Tajana GF. The effect of high and low molecular weight hyaluronic acid on mitogen-induced lymphocyte proliferation. Current Therapeutic Research 47: 437–443, 1990Google Scholar
  184. Percival SPB. Complications from use of sodium hyaluronate (Healonid) in anterior segment surgery. British Journal of Ophthalmology 66: 714–716, 1982PubMedCrossRefGoogle Scholar
  185. Percival SPB. Sodium hyaluronate in perspective: experiences from a four-year clinical trial. Transactions of the Ophthalmological Society (UK) 104: 616–620, 1985Google Scholar
  186. Pietrogrande V, Melanotte PL, D’Agnolo B, Ulivi M, Benigni GA, et al. Hyaluronic acid versus methylprednisolone intra-articularly injected for treatment of Osteoarthritis of the knee. Current Therapeutic Research 50: 691–701, 1991Google Scholar
  187. Pinals RS. Pharmacologic treatment of Osteoarthritis. Clinical Therapeutics 14: 336–346, 1992PubMedGoogle Scholar
  188. Polack FM, Demong T, Santaella H. Sodium hyaluronate (Healon®) in keratoplasty and IOL implantation. Ophthalmology 89: 425–431, 1982Google Scholar
  189. Ponzin D, Vecchia P, Toffano G, Giordano C, Bruni A. Characterization of macrophages elicited by intraperitoneal injection of hyaluronate. Agents and Actions 18: 544–549, 1986PubMedCrossRefGoogle Scholar
  190. Pop M. The clinical performance of viscoelastics during phacoemulsification. Proceedings of the National Ophthalmic Speakers Program (NOSP), Montreal, pp. 13–14, Medicopea International Inc, 1992Google Scholar
  191. Portis JM, Verne AZ, Hilton GF. Sodium hyaluronate, hyphema and vitreoretinal surgery. American Journal of Ophthalmology 101: 738–739, 1986PubMedGoogle Scholar
  192. Pruett RC, Schepens CL, Swann DA. Hyaluronic acid vitreous substitute. Archives of Ophthalmology 97: 2325–2330, 1979PubMedCrossRefGoogle Scholar
  193. Punzi L, Schiavon F, Ramonda R, Malatesta V, Gambari P, et al. Intra-articular hyaluronic acid in the treatment of inflammatory and noninflammatory knee effusions. Current Therapeutic Research 43: 643–647, 1988Google Scholar
  194. Punzi L, Schiavon F, Cavasin F, Ramonda R, Gambari PF, et al. The influence of intra-articular hyaluronic acid on PGE2 and cAMP of synovial fluid. Clinical and Experimental Rheumatology 7: 247–250, 1989PubMedGoogle Scholar
  195. Rafuse PE, Nichols BD. Effects of Healon vs. Viscoat on endothelial cell count and morphology and phacoemulsification and posterior chamber lens implantation. Canadian Journal of Ophthalmology 27: 125–129, 1992Google Scholar
  196. Raitta C, Setälä K. Trabeculectomy with the use of sodium hyaluronate. Acta Ophthalmologica 65: 709–714, 1987PubMedCrossRefGoogle Scholar
  197. Raitta C, Vesti E. The effect of sodium hyaluronate on the outcome of trabeculectomy. Ophthalmic Surgery 22: 145–149, 1991PubMedGoogle Scholar
  198. Rashid ER, Waring GO. Use of Healon® in anterior segment trauma. Ophthalmic Surgery 13: 201–203, 1982PubMedGoogle Scholar
  199. Ravalico G, Agolini G, Ammirati M, Bellavitis A. Use of viscoelastic substances of different molecular weight in IOL implantation in-the-bag. Italian Journal of Ophthalmology 4: 221–226, 1990Google Scholar
  200. Retanda G. Acido ialuronico nei processi di riparazione délie ulcere cutanee. Giornale Italiano di Dermatologia e Venereologia 120: 71–75, 1985Google Scholar
  201. Richter AW, Ryde EM, Zetterström EO. Non-immunogenicity of a purified sodium hyaluronate preparation in man. International Archives of Allergy and Applied Immunology 59: 45–48, 1979PubMedCrossRefGoogle Scholar
  202. Rivas Lacarte MP, Casasin T, Pumarola F, Alonso A. An alternative treatment for the reduction of tympanic membrane perforations: sodium hyaluronate. Acta Otolaryngologica 110: 110–114, 1990CrossRefGoogle Scholar
  203. Rizkalla G, Reiner A, Bogoch E, Poole AR. Studies of the articular cartilage proteoglycan aggrecan in health and Osteoarthritis. Journal of Clinical Investigation 90: 2268–2277, 1992PubMedCrossRefGoogle Scholar
  204. Roper-Hall MJ. Viscoelastic materials in the surgery of ocular trauma. Transactions of the Ophthalmololgical Society (UK) 103: 274–276, 1983Google Scholar
  205. Russell IJ, Michalek JE, Lawrence VA, Lessard JA, Briggs BT et al. A randomized, placebo (PI) and no-intervention (NI) controlled, trial of intra-articular (IA) 1% sodium hyaluronate in the treatment of knee Osteoarthritis. Abstract. Arthritis and Rheumatism 35 (Suppl): S132, 1992Google Scholar
  206. Ruusuvaara P, Pajari S, Setälä K. Effect of sodium hyaluronate on immediate postoperative intraocular pressure after extracapsular cataract extraction and IOL implantation. Acta Ophthalmologica 68: 721–727, 1990PubMedCrossRefGoogle Scholar
  207. Rydell N, Balazs EA. Effect of intra-articular injection of hyaluronic acid on the clinical symptoms of Osteoarthritis and on granulation tissue formation. Clinical Orthopaedics 80: 25–32, 1971CrossRefGoogle Scholar
  208. Saari H, Sorsa T, Konttinen YT. Reactive oxygen species and hyaluronate in serum and synovial fluid in arthritis. International Journal of Tissue Reactions 12: 81–89, 1990PubMedGoogle Scholar
  209. Sakimoto T, Tazawa Y, Fukamichi Y, Usui M, Masuda K. A clinical evaluation of 1% SL-1010 intraocular injection in penetrating keratoplasty. In Japanese. Yakuri to Chiryo 19: 397–419, 1991Google Scholar
  210. Sand BB, Marner K, Norm MS. Sodium hyaluronate in the treatment of keratoconjunctivitis sicca. Acta Ophthalmologica 67: 181–183, 1989PubMedCrossRefGoogle Scholar
  211. Sand BB, Work K, Skovbo A, Elboll P. Sodium hyaluronate and methylcelrulose in extracapsular cataract extraction. Acta Ophthalmologica 69: 65–67, 1991PubMedCrossRefGoogle Scholar
  212. Sato H, Takahashi T, Ide H, Fukushima T, Tabata M, et al. Antioxidant activity of synovial fluid, hyaluronic acid, and two subcomponents of hyaluronic acid. Arthritis and Rheumatism 31: 63–71, 1988PubMedCrossRefGoogle Scholar
  213. Sawa M, Murao M, Yanagi M, Shiratori K, Morita H. Study on safety of sodium hyaluronate by injection in the anterior chamber. In Japanese. Nippon Ganka Gakkai Zasshi 97: 448–454, 1993Google Scholar
  214. Schiavinato A, Lini E, Guidolin D, Pezzoli G, Botti P, et al. Intraarticular sodium hyaluronate injections in the Pond-Nuki experimental model of Osteoarthritis in dogs. Clinical Orthopaedics and Related Research 241: 286–299, 1989PubMedGoogle Scholar
  215. Schubert HD, Denlinger JL, Balazs EA. Exogenous Na-hyaluronate in the anterior chamber of the owl monkey and its effect on the intraocular pressure. Experimental Eye Research 39: 137–152, 1984PubMedCrossRefGoogle Scholar
  216. Shibata S. Clinical use of sodium hyaluronate (ARTZ®) in treatment of Osteoarthritis of the knee. Shinyaku to Rinsho 42: 126–130, 1993Google Scholar
  217. Shimmura S, Tsubota K, Oguchi Y, Fukumura D, Suematsu M, et al. Oxiradical-dependent photoemission induced by a phacoemulsification probe. Investigative Ophthalmology and Visual Science 33: 2904–2907, 1992PubMedGoogle Scholar
  218. Smedsrod B, Pertoft H, Eriksson S, Fraser JRE, Laurent TC. Studies in vitro on the uptake and degradation of sodium hyaluronate in rat liver endothelial cells. Biochemical Journal 223: 617–626, 1984PubMedGoogle Scholar
  219. Smith KD, Burt WL. Fluorescent viscoelastic enhancement. Journal of Cataract and Refractory Surgery 18: 572–576, 1992Google Scholar
  220. Smith MM, Ghosh P. The synthesis of hyaluronic acid by human synovial fibroblasts is influenced by the nature of the hyaluronate in the extracellular environment. Rheumatology International 7: 113–122, 1987PubMedCrossRefGoogle Scholar
  221. Spelling PF, Heise N, Toledo OMS. Glycosaminoglycans in the synovial fluids of patients with juvenile rheumatoid arthritis. Clinical and Experimental Rheumatology 9: 195–199, 1991PubMedGoogle Scholar
  222. Stamper RL, DiLoreto D, Schacknow P. Effect of intraocular aspiration of sodium hyaluronate on postoperative intraocular pressure. Ophthalmic Surgery 21: 486–490, 1990PubMedGoogle Scholar
  223. Stegmann R, Miller D. Extracapsular cataract extraction with hyaluronate sodium. Annals of Ophthalmolgy 813–815, 1982Google Scholar
  224. Stegmann R, Miller D. Use of sodium hyaluronate in severe penetrating ocular trauma. Annals of Ophthalmology 18: 9–13, 1986PubMedGoogle Scholar
  225. Steindler P, DeLiberato P, Beinat L, De Carli A. Effects of IAL and Healon on postoperative intraocular pressure after cataract surgery with intraocular lens implantation. Annals of Ophthalmology 23: 246–250, 1991PubMedGoogle Scholar
  226. Stenfors L-E. Treatment of tympanic membrane perforations with hyaluronan in an open pilot study of unselected patients. Acta Otolaryngologica 442 (Suppl.): 81–87, 1987aCrossRefGoogle Scholar
  227. Stenfors L-E. Repair of traumatically ruptured tympanic membrane using hyaluronan. Acta Otolaryngologica 442 (Suppl.): 88–91, 1987bCrossRefGoogle Scholar
  228. Stenkula S, Ivert L, Gislason I, Tornquist R, Weijdegard L. The use of sodium-hyaluronate (Healon) in the treatment of retinal detachment. Ophthalmic Surgery 435–437, 1981Google Scholar
  229. Storr-Paulsen A. Analysis of the short-term effect of two viscoelastic agents on the intraocular pressure after extracapsular cataract extraction. Acta Ophthalmologica 71: 173–176, 1993PubMedCrossRefGoogle Scholar
  230. Storr-Paulsen A, Larsen M. Long-term results of extracapsular cataract extraction with posterior chamber lens implantation. Acta Ophthalmologica 69: 766–769, 1991PubMedCrossRefGoogle Scholar
  231. Strachan RK, Smith P, Gardner DL. Hyaluronate in rheumatology and orthopaedics: is there a role?. Annals of the Rheumatic Diseases 49: 949–952, 1990PubMedCrossRefGoogle Scholar
  232. Stuart JC, Linn JG. Dilute sodium hyaluronate (Healon) in the treatment of ocular surface disorders. Annals of Ophthalmology 17: 190–192, 1985PubMedGoogle Scholar
  233. Subramanian N, Bunyaratavej N, Chan KM. The use of hyaluronic acid (Hyalgan) in the treatment of OA of the knee: results of a multicentre, randomised, double-blind (masked observer), placebo-controlled trial. Presented at the 11th Congress of the ASEAN Orthopaedic Association, Malaysia, November 20–23, 1991Google Scholar
  234. Suzu F, Hirasawa Y. Long-term use of ARTZ (high molecular weight sodium hyaluronate) in treatment of Osteoarthritis of the knee. In Japanese. Shinyaku to Chiryo 18: 225–230, 1990Google Scholar
  235. Suzuki Y, Yamaguchi T. EFfects of hyaluronic acid on macrophage phagocytosis and active oxygen release. Agents Actions 38: 33–37, 1993CrossRefGoogle Scholar
  236. Tengblad A, Laurent UBG, Lilja K, Cahill RNP, Engström-Laurent A, et al. Concentration and relative molecular mass of hyaluronate in lymph and blood. Biochemical Journal 236: 521–525, 1986PubMedGoogle Scholar
  237. Thomsen M, Simonsen AH, Andreassen TT. Comparison of sodium hyaluronate and methylcellulose in extracapsular cataract extraction. Acta Ophthalmologica 65: 400–405, 1987PubMedCrossRefGoogle Scholar
  238. Trabucchi E, Foschi D, Marazzi M, Radaelli E, Lucianetti A, et al. Prvention of wound dehiscence in severely obese patients with jejuno-ileal by-pass: the role of hyaluronic acid. Pharmatherapeutica 5: 233–239, 1988PubMedGoogle Scholar
  239. Tsuboi I, Kotera N, Shichijo S, Namba K, Suzuki K, et al. Effect of high molecular weight sodium hyaluronate (SL-1010) on human neutrophil function. In Japanese. Japanese Journal of Inflammation 3: 55–61, 1993Google Scholar
  240. Tsukanishi S, Nobuhara K. Clinical effect of SLM-10 (high molecular weight sodium hyaluronate) in patients with periarthritis of the shoulder. In Japanese. Japanese Pharmacology and Therapeutics 21 (Suppl. 21): 367–378, 1993Google Scholar
  241. Ueo T, Okumura H, Shimizu K, Kasai R. Changes of synovial fluid properties after intraarticular injection of high molecular weight hyaluronate in patients with rheumatoid arthritis. In Japanese. Japanese Journal of Inflammation 11: 169–173, 1991Google Scholar
  242. Usui M, Fukamichi YY, Tobari I, Shimizu K, Tanaka S. A phase III clinical comparative trial of sodium hyaluronate (SL-1010) in intraocular lens implantation. In Japanese. Yakuri to Chiryo 19: 377–396, 1991Google Scholar
  243. Vannini AM, Ferrari MP, Dalla Valle I, Magnolfi G, et al. The biological rationale underlying the therapeutic effectiveness of exogenous hyaluronic acid and low-frequency pulsed electromagnetic fields in pressure ulcer medical treatment. In Abatangelo & Davidson (Eds) Cutaneous Development, Aging and Repair. Fidia Research Series 18, pp. 81–95, Liviana Press, Padova, 1989Google Scholar
  244. Vatne HO, Syrdalen P. The use of sodium hyaluronate (Healon) in the treatment of complicated cases of retinal detachment. Acta Ophthalmologica 169–172, 1986Google Scholar
  245. Vuorio E, Einola S, Hakkarainen S, Penttinen R. Synthesis of underpolymerized hyaluronic acid by fibroblasts cultured from rheumatoid and non-rheumatoid synovitis. Rheumatology International 2: 97–102, 1982PubMedCrossRefGoogle Scholar
  246. Weigel PH, Frost SJ, McGary CT, LeBoeuf RD. The role of hyaluronic acid in inflammation and wound healing. International Journal of Tissue Reactions 10: 355–365, 1988PubMedGoogle Scholar
  247. Weigel PH, Fuller GM, LeBoeuf RD. A model for the role of hyaluronic acid and fibrin in the early events during the inflammatory response and wound healing. Journal of Theoretical Biology 11: 219–234, 1986CrossRefGoogle Scholar
  248. Wigren A, Falk J, Wik O. The healing of cartilage injuries under the influence of joint immobilization and repeated hyaluronic acid injections. Acta Orthopaedica Scandinavica 49: 121–133, 1978PubMedCrossRefGoogle Scholar
  249. Wilson RP, Lloyd J. The place of sodium hyaluronate in glaucoma surgery. Ophthalmic Surgery 17: 30–33, 1986PubMedGoogle Scholar
  250. Worrall JG, Bayliss MT, Edwards JCW. Morphological localization of hyaluronan in normal and diseased synovium. Journal of Rheumatology 18: 1466–1472, 1992Google Scholar
  251. Yamada T, Jikihara S, Funahashi M. Ocular response to viscous substances in rabbits. In Japanese. Folia Ophthalmologica 40: 269–274, 1989Google Scholar
  252. Yamamoto R, Tabata S, Mikasa M, Takagishi K, Ogawa N. Doserange finding study of SLM-10 (sodium hyaluronate injection) in patients with periarthritis scapulohumeralis. In Japanese. Japanese Pharmacology and Therapeutics 21 (Suppl. 2): 265–286, 1993aGoogle Scholar
  253. Yamamoto R, Tabata S, Mikasa M, Takagishi K, Ogawa N. Clinical trial of SLM-10 (sodium hyaluronate injection) compared with ARTZ® in patients with periarthritis scapulohumeralis. In Japanese. Yakuri to Chiryo 21: 285–307, 1993bGoogle Scholar
  254. Yasui T, Akatsuka A, Tobetto K, Hayaishi M, Ando T. The effect of hyaluronan on interleukin-1α-induced Prostaglandin E2 production in human osteoarthritic synovial cells. Agents Actions 37: 155–156, 1992PubMedCrossRefGoogle Scholar
  255. Yoshinoya S, Mizoguchi Y, Hashimoto Y, Yamada A, Uchida S, et al. Serum concentration of hyaluronic acid in healthy populations and in patients with rheumatoid arthritis — relationship to clinical disease activity of RA. In Japanese. Ryumachi 31: 381–390, 1991PubMedGoogle Scholar

Copyright information

© Adis International Limited 1994

Authors and Affiliations

  • Karen L. Goa
    • 1
  • Paul Benfield
    • 1
  1. 1.Adis International LimitedMairangi Bay, Auckland 10New Zealand

Personalised recommendations